The early signs were that markets were very impressed as they digested Eli Lilly’s (NYSE: LLY) data on its Alzheimer’s disease prospect, donanemab.
Shares in the US drug major were 4% higher in early trading on Wednesday after the firm presented positive results from the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in early symptomatic Alzheimer's.
Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer's disease rating scale (iADRS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze